Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rabbi, C
Right arrow Articles by Smerieri, F
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rabbi, C
Right arrow Articles by Smerieri, F
Haematologica, Vol 81, Issue 1, 15-19
Copyright © 1996 by Ferrata Storti Foundation


Clinical Trial

Stomach preservation in low- and high-grade primary gastric lymphomas: preliminary results

C Rabbi, E Aitini, G Cavazzini, M Cantore, ME Forghieri, F Pari, D Zamagni, A Mambrini, M Amadori, and F Smerieri

Department of Medical Oncology, Ospedale Carlo Poma, Mantua, Italy.

BACKGROUND: The optimal management of primary gastric lymphomas has yet to be defined. In the past surgery was advocated as the optimal first step for patients with PGL. Recently, an increasing number of studies suggest that chemotherapy is as effective as surgery. METHODS: Fourteen patients with PGL were treated with chemotherapy alone. For patients with low-grade lymphoma, chemotherapy consisted of mitoxantrone 5 mg/sqm on days 1 to 3. Treatment courses were administered every 3 weeks up to a maximum of 6 cycles. Patients with high-grade lymphoma received chemotherapy according to the CHOP schedule every 4 weeks up to a maximum of 6 cycles. Two patients with high-grade lymphoma were treated as low-grade lymphoma patients (one because of age and poor performance status, the other because she refused chemotherapy that would cause hair loss). Two patients with low-grade lymphomas who did not respond to mitoxantrone were crossed over to CHOP. RESULTS: All patients were evaluable for toxicity, 13 for response to therapy and survival. Toxicity was mild or moderate. Neither perforation nor hemorrhage was observed. Eleven patients achieved a complete remission (85%), 1 a partial remission (7.5%) and 1 underwent disease progression (7.5%). At a median follow-up of 12 months (range 4-44 months) all complete responders are alive and disease free. CONCLUSIONS: Although the number of evaluable patients is too small to draw any final conclusions, chemotherapy seems to be as effective as surgery in PGL, and stomach preservation improves the quality of life of the patients.


This article has been cited by other articles:


Home page
Ann. Surg. Oncol.Home page
G. Spectre, D. Libster, S. Grisariu, N. Da'as, D. B. Yehuda, Z. Gimmon, and O. Paltiel
Bleeding, Obstruction, and Perforation in a Series of Patients With Aggressive Gastric Lymphoma Treated With Primary Chemotherapy
Ann. Surg. Oncol., November 1, 2006; 13(11): 1372 - 1378.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
M. Binn, A. Ruskone-Fourmestraux, E. Lepage, C. Haioun, A. Delmer, P. Aegerter, A. Lavergne, C. Guettier, and J.-C. Delchier
Surgical resection plus chemotherapy versus chemotherapy alone: comparison of two strategies to treat diffuse large B-cell gastric lymphoma
Ann. Onc., December 1, 2003; 14(12): 1751 - 1757.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 1996 by the Ferrata Storti Foundation.